Market research
GBT Global Blood Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5B
- P/E ratio
- Not available
- Analyst target
- 64.5
- Dividend yield
- 0.0%
- Beta
- 0.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US37890U1088
- Market cap
- 5B
- P/E ratio
- Not available
- Analyst target
- 64.5
- Dividend yield
- 0.0%
- Beta
- 0.46
About
About Global Blood Therapeutics Inc
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GBT discussion.
5 years, 4 months ago
Global Blood Therapeutics, Inc is currently in a long term downtrend where the price is trading 23.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.1.
Global Blood Therapeutics, Inc's total revenue rose by 1859.0% to $41M since the same quarter in the previous year.
Its net income has increased by 35.6% to $-62M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.2% to $-50M since the same quarter in the previous year.
Based on the above factors, Global Blood Therapeutics, Inc gets an overall score of 4/5.